Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Drug Chem Toxicol ; 45(6): 2686-2698, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-1450322

ABSTRACT

Fluoroquinolones (FQs) are synthetic and broad-spectrum antimicrobial drugs derived from nalidixic acid. FQs are used against SARS-CoV-2 in our country, and for the treatment of some urinary tract diseases, gastrointestinal diseases, respiratory tract diseases, sexually transmitted diseases, and dermatological diseases. The present study investigated the effect of 1-,7-,14-day treatments of three different FQ derivatives; ciprofloxacin (CIP) 80 mg/kg/day, levofloxacin (LVX) 40 mg/kg/day, and moxifloxacin (MXF) 40 mg/kg/day, on biochemical parameters, lipid peroxidation, antioxidant enzymes, and immunotoxicity. 72 Wistar albino male rats were distributed to four groups including 18 rats in each group and were sacrificed on three different time points. The 14-day treatment of MXF significantly reduced the levels of aspartate aminotransferase (AST), glucose, reduced glutathione (GSH), malondialdehyde (MDA), catalase (CAT), myeloperoxidase (MPO), adenosine deaminase (ADA), and glutathione peroxidase (GPx). Furthermore, 14-day treatment of LVX increased liver [GSH, MPO, ADA, superoxide dismutase (SOD)], and GSH (erythrocyte) levels; whereas it significantly reduced the levels of AST, TG (triglycerides) and associated parameters levels in all the tissues (MDA), erythrocytes, and liver (MPO, CAT, SOD, GPx). After 14-day treatment of CIP; the erythrocyte levels of GSH, MPO, GPx, and CAT significantly decreased; whereas the levels of glucose, creatinine, MPO (liver), and GST (kidney and erythrocyte) significantly increased. It has been concluded that FQ derivatives used in this experiment did not display any correlation in terms of the efficacies in the different time points and tissues. Thus, it is recommended to use such FQ derivatives considering the duration of use and target tissue.


Subject(s)
Antioxidants , COVID-19 , Animals , Rats , Antioxidants/pharmacology , Antioxidants/metabolism , Catalase/metabolism , Glutathione Peroxidase/metabolism , Peroxidase/pharmacology , Adenosine Deaminase/pharmacology , Fluoroquinolones/toxicity , Creatinine , Levofloxacin/pharmacology , Moxifloxacin/pharmacology , Nalidixic Acid/pharmacology , Rats, Wistar , SARS-CoV-2 , Lipid Peroxidation , Glutathione/metabolism , Malondialdehyde , Superoxide Dismutase/metabolism , Triglycerides , Aspartate Aminotransferases , Glucose , Ciprofloxacin/pharmacology , Oxidative Stress
SELECTION OF CITATIONS
SEARCH DETAIL